Welcome to our dedicated page for Inhibitor Therap SEC filings (Ticker: INTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inhibitor Therapeutics, Inc. (INTI), a biotechnology company developing itraconazole-based oncology therapies. These regulatory documents offer detailed insight into the company’s clinical programs, material agreements, and equity incentive structures beyond what is available in brief press releases.
For Inhibitor Therapeutics, key filings can include annual reports on Form 10-K and quarterly reports on Form 10-Q, where investors may review narrative discussions of the itraconazole development program for basal cell carcinomas in Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome), risk factor disclosures, and descriptions of licensed intellectual property such as the "New Angiogenesis Inhibitors" patents from Johns Hopkins University. Current reports on Form 8-K highlight specific material events, such as the disclosed performance-based master services agreement with Frameshift Management, Inc. to support biostatistics, regulatory, business development, and strategic consulting for the company’s BCCNS programs, and the approval of the Inhibitor Therapeutics, Inc. 2025 Equity Incentive Plan.
Through this filings page, users can also monitor exhibits attached to reports, which may include the full text of agreements referenced in summaries. Forms related to equity awards and potential insider transactions, such as Form 4 when applicable, help clarify how the 2025 Equity Incentive Plan and other compensation arrangements are implemented over time.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight important terms in agreements, and surface key points from lengthy documents. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms for INTI appear promptly, while AI-generated overviews help readers quickly understand how each filing relates to Inhibitor Therapeutics’ oncology development strategy and capital structure.
Inhibitor Therapeutics, Inc. furnished an update on its itraconazole program for Gorlin Syndrome, covering clinical progress, formulation strategy and intellectual property plans. The company is running a three-way crossover pharmacokinetic study in healthy adults in Malaysia under fasting conditions, in collaboration with Avior Bio.
Period 2 dosing is scheduled for April 10, 2026 and Period 3 for April 24, 2026, with plasma samples expected to be shipped for bioanalysis on or about May 1, 2026. Inhibitor believes this PK study is expected to be the final clinical study before a planned New Drug Application for surgically eligible basal cell carcinomas in BCCNS.
The program uses a proprietary amorphous itraconazole formulation intended to improve solubility and absorption versus conventional crystalline drug. Inhibitor is also preparing a new global patent application on this formulation, which it expects would be owned by the company without ongoing royalty obligations and would complement its existing oncology-focused IP portfolio.
Inhibitor Therapeutics, Inc. is a pre‑revenue pharmaceutical development company focused on repurposing the antifungal itraconazole to treat basal cell carcinoma nevus syndrome (Gorlin Syndrome). Its lead evidence comes from the HP2001 Phase IIb study in 38 patients with 477 baseline lesions, where per‑lesion objective response was reported at 57.7% and patient‑level disease control at 97.4%.
The company has an FDA Type C meeting granted for its BCCNS program, with written responses expected in May 2026, and holds orphan‑drug designation for itraconazole in this indication. It has engaged Avior Bio to create a proprietary micronized/amorphous itraconazole formulation and licenses angiogenesis‑related IP from Johns Hopkins, aiming to build layered exclusivity.
INTI has minimal operations, only eight employees, no commercial products and no current revenue. It depends on new capital and potential strategic transactions, including a February 2026 securities purchase agreement for $3 million plus warrant funding that is not assured to close. The filing highlights substantial risks: early‑stage clinical status, regulatory uncertainty around its proposed per‑lesion endpoint strategy and 505(b)(2) path, reliance on a small leadership team, intense competition, and a thin, volatile OTCQB trading market. Management acknowledges significant doubt about the ability to continue as a going concern without additional financing or deals.
Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to raise $3,000,000. The company agreed to sell 12,000,000 shares of common stock and issue a warrant to purchase up to 7,000,000 additional shares at $0.25 per share and accompanying warrant.
The warrant will be exercisable for three years at an exercise price of $0.35 per share, which could provide up to an additional $2,450,000 in gross proceeds if fully exercised. As of the filing date, the financing had not yet closed, and the investor agreed under a lock-up to refrain from selling the financing and warrant shares for nine months after the SPA date or until a change in control.
Inhibitor Therapeutics (INTI) reported Q3 2025 results marked by ongoing development work and no product revenue. The company posted a net loss of $712,184 for the quarter and $2,004,972 for the nine months. Operating expenses were steady, with R&D $377,789 and G&A $363,426 in Q3. Interest income was $29,031 in Q3.
Cash and cash equivalents were $2,976,658 as of September 30, 2025 (from $5,606,863 at year-end), reflecting net cash used in operations of $2,630,205 year-to-date. The balance sheet shows $3,000,000 in deferred royalty advances tied to the BCCNS program. The company advanced regulatory preparations around itraconazole for BCCNS, engaged Avior for a finalized formulation and a PK crossover study, and applied to FDA’s RDEA pilot. Subsequent events include a 2025 Equity Incentive Plan for up to 20,000,000 shares subject to shareholder approval and a performance-based consulting agreement with Frameshift featuring warrant eligibility upon defined milestones. 172,573,545 shares were outstanding as of November 13, 2025.
Inhibitor Therapeutics (INTI) reported two corporate actions. The company entered a performance-based master services agreement with Frameshift Management, Inc. to provide biostatistics, regulatory, business development and strategic consulting supporting its basal cell carcinoma programs in Gorlin’s syndrome. Services commenced on October 21, 2025, with compensation at a previously agreed rate and unvested equity compensation realized only after requirements described in the agreement.
The Board also approved the 2025 Equity Incentive Plan, reserving up to 20,000,000 shares of common stock for awards, including options, RSUs, and other stock- or cash-based awards. Shareholder approval is planned within 12 months of adoption; if not received in time, the plan and any awards made under it will terminate.